Phase 2 Macular Degeneration Trial, Recruiting NCT06141460 Sponsor: Shanghai Refreshgene Technology Co., Ltd. Condition: Macular Degeneration
Back to Macular Degeneration

Phase 2 Macular Degeneration Trial, Recruiting

NCT06141460
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to follow the study procedures throughout the trial.
  • People aged 50 years or older.
  • People who have been clinically diagnosed with a condition called choroidal neovascularisation (CNV) caused by wet age-related macular degeneration (wet AMD), which involves abnormal blood vessel growth under the retina.
  • People whose vision in the eye being studied falls within a specific range — roughly between 20/800 and 20/40 on a standard eye chart — and whose other eye has at least a minimum level of vision (roughly 20/400 or better) (confirm with trial site for exact letter scores).
  • People whose condition has shown a response to a type of treatment called anti-VEGF therapy, which is used to slow abnormal blood vessel growth in the eye.

Who may not be able to join:

  • People who have other eye diseases (apart from wet AMD) in the eye being studied that could affect treatment or make the results harder to interpret, as determined by the study investigator.
  • People whose abnormal blood vessel growth or macular swelling in the eye being studied is caused by something other than AMD.
  • People with glaucoma that is not well controlled.
  • People with high blood pressure that remains uncontrolled even with medication.
  • People who are pregnant or breastfeeding, or people of reproductive age who are unwilling to use effective contraception for the duration of the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 8602223346434

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Refreshgene Technology Co., Ltd.
Registry
ClinicalTrials.gov
Start date
12 December 2023
Est. completion
15 April 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety and tolerability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov